Quick Takeaways
- Muna Bhanji has 4 issuer positions tracked on this page.
- Estimated disclosed ownership value: $2,695,082.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Muna Bhanji
- Location
- South San Francisco, CA
- Summary
- The estimated net worth of Muna Bhanji is at least $2,695,082 dollars as of 23 Jun 2025. Muna Bhanji is the Director of VERACYTE, INC. and owns shares of VERACYTE, INC. (VCYT) stock worth about $1.13M. Muna Bhanji is the Director of CYTOKINETICS INC and owns shares of CYTOKINETICS INC (CYTK) stock worth about $699K. Muna Bhanji is the Director of ARDELYX, INC. and owns shares of ARDELYX, INC. (ARDX) stock worth about $637.3K. Muna Bhanji is the Director of Intellia Therapeutics, Inc. and owns shares of Intellia Therapeutics, Inc. (NTLA) stock worth about $226.3K.
- Signature
- /s/ Elizabeth Grammer, Attorney-in-Fact for Muna Bhanji
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Muna Bhanji and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: VERACYTE, INC. ($1,132,521).
- Past-year value change for that position: -$122,367.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Muna Bhanji
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| VCYT | VERACYTE, INC. | Director | $1,132,521 | -$122,367 | -9.8% | 18 Jun 2025 |
| CYTK | CYTOKINETICS INC | Director | $698,952 | -$43,227 | -5.8% | 15 May 2025 |
| ARDX | ARDELYX, INC. | Director | $637,281 | 18 Jun 2025 | ||
| NTLA | Intellia Therapeutics, Inc. | Director | $226,328 | 11 Jun 2025 |
Insider Transactions Reported by Muna Bhanji:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.